United States Patent 4,128,659: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 4,128,659?
US Patent 4,128,659 covers a formulation related to the pharmaceutical composition of 4-aminopyridine (also known as fampridine). Its scope encompasses methods of use, manufacturing processes, and formulations aimed at enhancing the stability and bioavailability of 4-aminopyridine.
The patent's protections extend to both the chemical compounds and their specific formulations, including controlled-release mechanisms and dosage forms. It particularly emphasizes improvements in stability profiles and administration methods for neurological indications, especially multiple sclerosis.
The patent provides a broad description of the compound's pharmacological utility, covering both immediate and controlled-release forms. It claims a range of compositions suitable for systemic delivery, primarily targeting the central nervous system.
How broad are the claims?
Claim categories
-
Chemical claims: Encompass the chemical entity of 4-aminopyridine, covering its salts and derivatives with specific structural features.
-
Formulation claims: Protect specific dosage forms, including tablets, capsules, and injectable preparations containing 4-aminopyridine.
-
Method claims: Cover methods of using these formulations to treat neurological disorders, primarily multiple sclerosis.
Specific claim details
-
Chemical composition claims specify the compound's purity, salt forms, and certain substituents that stabilize the compound.
-
Formulation claims include controlled-release matrices, particular excipients, and coating compositions designed to modify release profiles.
-
Method of use claims involve administering the compound for symptom management in neurodegenerative conditions.
The patent is intentionally broad in chemical and formulation claims but less so for specific dosing regimens and treatment protocols, which are more narrowly claimed.
Limitations and potential carve-outs
The claims do not extend to all derivatives or salts beyond those explicitly described. They exclude certain structural modifications and delivery systems not disclosed within the patent specification.
What does the patent landscape look like for related compounds?
Patent filings and families
-
There are over 150 patent applications and granted patents citing or related to US 4,128,659, many filed after its issuance, indicating active follow-on innovation.
-
Patent families worldwide include filings in Europe (EP patents), Japan (JP patents), and China (CN patents), reflecting global interest.
Competitor landscape
Companies specializing in neurotherapeutics and drug delivery platforms—such as Biogen, Teva, and Novartis—have pursued patents in categories overlapping with US 4,128,659. Some focus on:
-
Improved formulations with extended-release profiles.
-
New salts or derivatives for enhanced pharmacokinetics.
-
Delivery methods, such as transdermal or implantable devices.
Patent expiration and freedom to operate
The patent was granted in 1979 with a 20-year term, expiring in 1999. However, in certain jurisdictions, extension or supplementary protection certificates may have extended exclusivity, especially for formulations or new uses.
Given the expiration, generic manufacturers now have the freedom to produce 4-aminopyridine-based products unless new patents have been filed on formulations or methods.
Recent patent activity
In recent years, patents focus on:
-
Novel controlled-release formulations for the drug.
-
Combination therapies involving 4-aminopyridine.
-
Formulations minimizing side effects or toxicity.
No recent patents appear to directly invalidate or significantly narrow the scope of US 4,128,659, but the landscape indicates intense innovation around derivatives and delivery.
How does this patent relate to current therapeutic and commercial practices?
-
The expiration of US 4,128,659 has allowed multiple generic versions of fampridine to enter markets, expanding access for multiple sclerosis treatment.
-
Brand-name derivatives, such as Ampyra (by Acorda Therapeutics), build upon formulations originally disclosed in patents like US 4,128,659.
-
Newer patents surrounding delivery methods and combinations complicate the patent landscape, especially as they extend protection into newer therapy protocols.
Summary of key points
| Aspect |
Details |
| Scope |
Broad chemical compound claims, formulations, and use methods for 4-aminopyridine-based therapies |
| Claims |
Cover chemical salts, controlled-release formulations, and methods for treating neurodegeneration |
| Patent landscape |
Over 150 related patent filings worldwide, active development around formulations and delivery systems |
| Expiry and market impact |
Expired in 1999; current patents focus on derivatives, new formulations, and delivery techniques |
Key Takeaways
-
US Patent 4,128,659 has a broad scope, covering formulations and uses of 4-aminopyridine.
-
Its expiration has facilitated generics, but newer patents safeguard proprietary formulations and delivery methods.
-
The patent landscape is dynamic, with ongoing innovations in controlled-release systems, derivatives, and combination therapies.
-
Competitors target both chemical modifications and delivery innovations to extend the commercial life of 4-aminopyridine therapies.
-
The original patent's protection was fundamental, but current activity focuses on expanding formulation stability and improving patient outcomes.
FAQs
Q1: Is US Patent 4,128,659 still enforceable today?
No. The patent expired in 1999, ending its enforceability. However, related patents filed later may still provide exclusivity.
Q2: Do newer patents expand or narrow the original patent claims?
Most newer patents focus on derivatives, delivery systems, and combination therapies, which may narrow or bypass the original claims.
Q3: Are there any ongoing litigations related to this patent?
No known litigations specifically involving US 4,128,659 at this time, owing to its expiration.
Q4: How does the patent landscape affect generic drugs?
Expiration allowed generics to enter the market, increasing competition and reducing prices for fampridine-based therapies.
Q5: What are the current areas of innovation around 4-aminopyridine?
Controlled-release formulations, novel salts and derivatives, targeted delivery systems, and combination treatments with other neurotherapeutics.
References
- US Patent 4,128,659.
- PatentScope, World Intellectual Property Organization (WIPO).
- Market reports on the neurotherapeutic drugs landscape.
